CEL SCI Business Summary

CEL-SCI Corporation is a clinical-stage biotechnology firm primarily focused on the development of immunotherapy for the treatment of cancer and infectious diseases. The company’s business model centers on the clinical advancement and eventual commercialization of its flagship candidate, Multikine (Leukocyte Interleukin, Injection), through direct product sales or strategic licensing partnerships. Revenue generation is currently transitioning from capital raises and interest income toward commercial-stage activities following the submission of its Biologics License Application (BLA) for Multikine as a first-line neoadjuvant therapy for advanced primary head and neck cancer. The company operates through two primary technological platforms: the Multikine immunotherapy program and the Ligand Epitope Antigen Presentation System (LEAPS) for infectious diseases and autoimmune disorders. CEL-SCI competes directly with major oncology players such as Merck & Co. (Keytruda), Bristol-Myers Squibb (Opdivo), and AstraZeneca (Imfinzi). Unlike these competitors who largely target recurrent or metastatic disease, CEL-SCI occupies a unique market niche by positioning its therapy as a pre-surgical intervention intended to bolster the immune system before standard-of-care surgery and radiation. The leadership team is anchored by Chief Executive Officer Geert Kersten, who has led the company since 1987 and has been instrumental in navigating the long-term clinical trial process for Multikine. Dr. Eyal Talor serves as the Senior Vice President of Research and Development, bringing over three decades of expertise in immunology and clinical product development to oversee the company's core scientific programs. The executive suite is supported by Patricia B. Przybylski, the Chief Financial Officer, who manages the firm’s capital structure and fiscal strategy. Historically founded by the late Maximilian de Clara, the company maintains a board of directors with deep regulatory and clinical experience, including members such as Robert Watson and Dr. Gregory Brown. CEL-SCI is notable for its high level of retail investor engagement and its persistent focus on the neoadjuvant treatment paradigm, distinguishing its strategic direction from the broader immunotherapy sector's focus on late-stage palliative care.